Benzimidazole resistant Haemonchus contortus in a wildlife park

Anthelmintic resistance (AR) of ruminant gastrointestinal nematodes (GINs) constitutes a major problem worldwide. Among GINs, the abomasal blood-feeding parasite Haemonchus contortus is particularly pathogenic and may show resistance against all major anthelmintic substance classes. In the present study, the death of a 1,5 year-old European bison (Bison bonasus) from a German wildlife park due to haemonchosis despite frequent anthelmintic treatment of the herd with fenbendazole as well as doramectin prompted an investigation regarding AR. Pooled faecal samples were collected from four different bison groups as well as from mouflons (Ovis orientalis), elk (Alces alces), reindeer (Rangifer tarandus), sika deer (Cervus nippon), Persian fallow deer (Dama mesopotamica) and red deer (Cervus elaphus) housed by the wildlife park. After coproscopical examination, faecal larval cultures were established. Haemonchus contortus-positive larval cultures were further examined for genetic polymorphisms associated with benzimidazole resistance at codons 167 and 200 of the β-tubulin isotype 1 gene by real-time pyrosequencing. Infections with H. contortus were detected in all four bison groups, as well as in mouflons. In five samples, representing two bison groups and the mouflons, the frequency of the resistance-associated single-nucleotide polymorphism (SNP) at codon 200 was 100%. In contrast, resistance-associated SNPs were not detected at codon 167. In addition, faecal egg counts from two bison before and 14 days after parenteral doramectin treatment indicated possible macrocyclic lactone resistance. Detection of anthelmintic resistant nematodes in these animals was especially concerning in the light of planned reintroduction into the wild. As helminth control in zoological gardens and wildlife parks relies mostly on anthelmintic treatment due to restricted possibilities regarding management practices such as rotational grazing, care should be taken to avoid underdosing or unnecessary frequent treatments facilitating the development of AR.